New hope for tough lung cancer? early trial combines two drugs to fight recurrence.

NCT ID NCT07550842

First seen May 07, 2026 · Last updated May 07, 2026

Summary

This early-stage study tests a new drug (BL0020) combined with an immunotherapy (Toripalimab) in people with extensive-stage small cell lung cancer that returned after initial treatment. About 33 adults will take part to see if the combination is safe and tolerable, and to check if it shrinks tumors. The goal is to find a better option for a cancer that currently has limited treatments after first-line therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Shanghai Chest Hospital

    Shanghai, 200030, China

  • Shanghai Pulmonary Hospital

    Shanghai, 200433, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, Zhejiang, 317000, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, 213003, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.